Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 10, Issue 6, 2011, Pages 470-476

  Haworth, Charles S ^a   Sharples, Linda ^b   Hughes, Vikki ^a   Elkin, Sarah L ^c,d   Hodson, Margaret E ^c   Conway, Steven P ^e   Etherington, Christine ^e   Elborn, J Stuart ^f   Rendall, Jackie ^f   Wheaton, Ella ^b   Kadri, Emma ^a   Elliott, Jane ^a   Barker, Helen C ^a   Bearcroft, Philip W P ^g   Hlaing, Thinn ^g   Compston, Juliet E ^h  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d ST MARY S HOSPITAL   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f BELFAST CITY HOSPITAL   (United Kingdom)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Bone mineral density; Cystic fibrosis; Fractures; Osteoporosis

Indexed keywords

CALCIUM; COLECALCIFEROL; COLLAGEN TYPE 1; PLACEBO; RISEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; GASTROINTESTINAL SYMPTOM; HIP; HUMAN; LUMBAR SPINE; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VERTEBRA FRACTURE;

ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; HUMANS; MALE; SINGLE-BLIND METHOD;

EID: 81455158920     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.07.007     Document Type: Article

References (29)

1. Aris R.M. on behalf of the Cystic Fibrosis Foundation Consensus Bone Health Group. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005, 90:1888-1896.
2. Buntain H.M., Schluter P.J., Bell S.C., et al. Controlled longitudinal study of bone mass accrual in Australian children and adolescents with cystic fibrosis. Thorax 2006, 61(2):146-154.
3. Haworth C.S., Selby P.L., Horrocks A.W., Mawer E.B., Adams J.E., Webb A.K. A prospective study of change in bone mineral density over one year in 114 adults with cystic fibrosis. Thorax 2002, 57:719-723.
4. Shead E.F., Haworth C.S., Condliffe A.M., McKeon D.J., Scott M.A., Compston J.E. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 2007, 62(7):650-651.
5. Le Heron L., Guillaume C., Velard F., et al. J Cyst Fibros 2010, 9(1):69-72.
6. Haworth C.S., Selby P.L., Webb A.K., et al. Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax 2004, 59:613-617.
7. Shead E.L., Haworth C.S., Gunn E., Bilton D., Scott M.A., Compston J.E. Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. Am J Respir Crit Care Med 2006, 174(3):306-311.
8. Shead E.F., Haworth C.S., Barker H.C., Bilton D., Compston J.E. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J Cyst Fibros 2010, 9(2):93-98.
9. National Institute for Health and Clinical Excellence. Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women June 2007, NICE, London.
10. National Institute for Health and Clinical Excellence. Final appraisal determination. Alendronate, etidronate, Risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women June 2007, NICE, London.
11. Homik J., Cranney A., Shae B., et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000, 2. CD001347.
12. Haworth C.S., Selby P.L., Adams J.E., Mawer E.B., Horrocks A.W., Webb A.K. The effect of intravenous pamidronate in adults with cystic fibrosis. Thorax 2001, 56:314-316.
13. Chapman I., Greville H., Ebeling P.R., et al. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). Clin Endocrinol 2009, 70:838-846.
14. Aris R.M., Lester G.E., Caminiti M., et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med 2004, 169:77-82.
15. Papaioannou A., Kennedy C.C., Frietag A., et al. Alendroante once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS Trial). Chest 2008, 134:794-800.
16. Haworth C.S., Selby P.L., Webb A.K., Mawer E.B., Adams J.E., Freemont A.J. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis. Lancet 1998, 352:1753-1754.
17. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42(11):2309-2318.
18. Reid D.M., Hughes R.A., Laan R.F., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner 2000, 15(6):1006-1013.
19. Pearson J., Dequeker J., Henley M., et al. European Semi-Anthropomorphic spine phantom for the calibration of bone densitometers-assessment of precision, stability, and accuracy-the European Quantitation of Osteoporosis Study Group. Osteoporos Int 1995, 5:174-184.
20. Looker A.C., Wahner H.W., Dunn W.L., et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998, 8:468-489.
21. Garland S.W., Lees B., Stevenson J.C. DXA longitudinal quality control: a comparison of inbuilt quality assurance, visual inspection, multi-rule Shewhart charts and Cusum analysis. Osteoporos Int 1997, 7:231-237.
22. Genant H.K., Jergas M. Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporos Int 2003, 14(Suppl 3):S43-S55.
23. Moher D. CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated Standards of Reporting Trials. JAMA 1998, 279(18):1489-1491.
24. Haworth C.S., Sharples L., Hughes V., et al. Multicentre randomised double blind placebo controlled trial assessing the effect of weekly risedronate on bone mineral density in adults with cystic fibrosis. J Cyst Fibros 2010, (Suppl 1):S85.
25. Haworth C.S., Sharples L., Hughes V., et al. Two-year multicenter, randomised, double-blind, placebo-controlled trial assessing the effect of weekly risedronate on bone mineral density in adults with CF. Pediatr Pulmonol 2010, (Suppl 33):423.
26. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
27. Pecherstorfer M., Jilch R., Sauty A., et al. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res 2000, 15(1):147-154.
28. Haworth C.S., Selby P.L., Webb A.K., Adams J.E., Freemont T.J. Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis. Lancet 1999, 353(9167):1886.
29. Compston J.E., Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 2006, 368:973-974.